450 related articles for article (PubMed ID: 15218539)
1. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
Hannan AJ
Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
[TBL] [Abstract][Full Text] [Related]
2. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.
van Dellen A; Grote HE; Hannan AJ
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1007-19. PubMed ID: 16445565
[TBL] [Abstract][Full Text] [Related]
3. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
Spires TL; Hannan AJ
FEBS J; 2005 May; 272(10):2347-61. PubMed ID: 15885086
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
Nithianantharajah J; Hannan AJ
Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
[TBL] [Abstract][Full Text] [Related]
5. Modeling brain reserve: experience-dependent neuronal plasticity in healthy and Huntington's disease transgenic mice.
Nithianantharajah J; Barkus C; Vijiaratnam N; Clement O; Hannan AJ
Am J Geriatr Psychiatry; 2009 Mar; 17(3):196-209. PubMed ID: 19454847
[TBL] [Abstract][Full Text] [Related]
6. [Huntington's disease: clinical and molecular genetics].
Warita H; Shiro Y; Kashihara K; Abe K
Nihon Rinsho; 1999 Apr; 57(4):896-9. PubMed ID: 10222786
[TBL] [Abstract][Full Text] [Related]
7. Huntington's disease: which drugs might help patients?
Hannan AJ
IDrugs; 2004 Apr; 7(4):351-8. PubMed ID: 15057641
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions.
Bates GP; Davies SW
Mol Med Today; 1997 Nov; 3(11):508-15. PubMed ID: 9430787
[TBL] [Abstract][Full Text] [Related]
9. Huntington's disease: the current state of research with peripheral tissues.
Sassone J; Colciago C; Cislaghi G; Silani V; Ciammola A
Exp Neurol; 2009 Oct; 219(2):385-97. PubMed ID: 19460373
[TBL] [Abstract][Full Text] [Related]
10. [Huntington disease--yet another mad protein?].
Petersén A; Hansson O; Brundin P
Lakartidningen; 2001 Dec; 98(50):5756-8, 5761. PubMed ID: 11789098
[TBL] [Abstract][Full Text] [Related]
11. Trinucleotide repeats and neurodegenerative disease.
Everett CM; Wood NW
Brain; 2004 Nov; 127(Pt 11):2385-405. PubMed ID: 15329351
[TBL] [Abstract][Full Text] [Related]
12. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.
Margolis RL; O'Hearn E; Rosenblatt A; Willour V; Holmes SE; Franz ML; Callahan C; Hwang HS; Troncoso JC; Ross CA
Ann Neurol; 2001 Sep; 50(3):373-80. PubMed ID: 11558794
[TBL] [Abstract][Full Text] [Related]
13. CAG repeat disorder models and human neuropathology: similarities and differences.
Yamada M; Sato T; Tsuji S; Takahashi H
Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
[TBL] [Abstract][Full Text] [Related]
14. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
15. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease.
Mo C; Hannan AJ; Renoir T
Neurosci Biobehav Rev; 2015 May; 52():178-92. PubMed ID: 25770041
[TBL] [Abstract][Full Text] [Related]
16. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
Bauer PO; Nukina N
J Neurochem; 2009 Sep; 110(6):1737-65. PubMed ID: 19650870
[TBL] [Abstract][Full Text] [Related]
17. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice.
Nithianantharajah J; Barkus C; Murphy M; Hannan AJ
Neurobiol Dis; 2008 Mar; 29(3):490-504. PubMed ID: 18165017
[TBL] [Abstract][Full Text] [Related]
18. [Molecular biology of polyglutamine diseases].
Owecki M; Kozubski W
Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
[TBL] [Abstract][Full Text] [Related]
20. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
